patent expiration
Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach
Merck; Keytruda; subcutaneous injection; FDA approval; Keytruda Qlex; patent expiration; biosimilars; checkpoint inhibitors; solid tumors; cancer immunotherapy